ACE and diabetes mellitus: Data from the Audit show that prescription of ACE inhibitors and ARBs for AI/AN patients with diabetes increased substantially, from 42% in 1997 to 74% in 2002, and then remained steady, ranging from 68% to 73% each year through 2015 (Figure 3).